Your session is about to expire
← Back to Search
Trimethoprim Sulfamethoxazole for Chronic Obstructive Pulmonary Disease
Study Summary
This trial will test whether treating airway colonization with the fungus Pneumocystis jirovecii (PJ) will improve outcomes for patients with acute exacerbations of COPD.
- Chronic Obstructive Pulmonary Disease Exacerbation Acute
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently taking steroids as part of your treatment.You are allergic or have a strong sensitivity to trimethoprim-sulfamethoxazole.You currently have cancer that is actively being treated with chemotherapy, except for non-melanoma skin cancer.You have other lung conditions that could interfere with the study.You have problems with your digestive system that would make it difficult for your body to absorb medications.You are currently taking medications like coumadin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide, or glyburide.Your doctors believe that you may only live for three more months or less.
- Group 1: TMP-SMX
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research currently calling for new participants?
"According to clinicaltrials.gov, the trial is actively searching for potential patients and has been since it was initially posted on September 28th 2022; no new updates have transpired since then."
Does my profile meet the criteria to partake in this trial?
"This clinical trial seeks 30 individuals aged 40 to 89 years that have been diagnosed with COPD and admitted due to an exacerbation. To be eligible, they must also produce a sputum sample, not have severely impaired kidney function (CrCl ≥ 60), AST/ALT values ≤ 5 times the upper limit of normal, previously enrolled in EPIC Study with Pneumocystis jirovecii detected in their sputum sample and currently being treated with steroids. Furthermore, participants need to demonstrate willingness and ability to provide consent for this study."
What aims is this experiment attempting to accomplish?
"This three-month long study aims to gauge the Change in COPD Assessment Test. Secondary objectives consist of Interval between exacerbations of COPD, measured by days; Need for medications to treat COPD, quantified through the amount of drugs used; and Need for mechanical ventilation, evaluated based on participant's necessity thereof."
Is this study open to individuals who have not yet reached the age of 85?
"Participants that are accepted into this trial must have attained the age of 40, but should not be older than 89."
What is the sample size for this medical research endeavor?
"Affirmative. According to the info logged on clinicaltrials.gov, this investigative trial is open for recruitment and was initially announced on September 28th 2022. The project requires 30 individuals from a single site."
Share this study with friends
Copy Link
Messenger